Lack of Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer.
Early breast cancer
Neutrophil-to-lymphocyte ratio
Prognostic factor
Journal
Breast care (Basel, Switzerland)
ISSN: 1661-3791
Titre abrégé: Breast Care (Basel)
Pays: Switzerland
ID NLM: 101254060
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
11
03
2022
accepted:
24
05
2022
entrez:
2
1
2023
pubmed:
3
1
2023
medline:
3
1
2023
Statut:
ppublish
Résumé
Breast cancer is a highly heterogeneous disease with large differences in the risk of recurrence. An elevated neutrophil-to-lymphocyte ratio (NLR) is correlated with a poor prognosis in a variety of tumors, and although it is still controversial in breast cancer, there are multiple studies, including meta-analysis, suggesting this. The purpose of this study was to analyze the prognostic value of preoperative NLR in an Argentine population of patients with nonmetastatic breast cancer, not exposed to neoadjuvant treatment. Retrospective multicenter cohort study that includes patients over 18 years of age from three centers in the city and province of Buenos Aires who have had surgery for early breast cancer between January 1, 1999, and December 31, 2014. Based on the previous literature, a cutoff value of 2.0 was defined. A total of 791 patients were eligible for the analysis. Median age was 55 years (IQR 45-65). Median NLR was 1.92 (IQR 1.50-2.56). The distribution of groups according to the 8th edition of the AJCC was 54.1% for stage I, 35.6% stage II, and 10.4% stage III. Among the different tumor phenotypes, 79.0% were HR+/HER2-, 11.4% were HR+ or-/HER2+, and 9.2% were HR-/HER2-. With a median follow-up of 5.3 years, 112 patients (14.2%) had disease recurrence. Stage III patients had a higher NLR than stage I and stage II patients ( We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias.
Sections du résumé
Background
UNASSIGNED
Breast cancer is a highly heterogeneous disease with large differences in the risk of recurrence. An elevated neutrophil-to-lymphocyte ratio (NLR) is correlated with a poor prognosis in a variety of tumors, and although it is still controversial in breast cancer, there are multiple studies, including meta-analysis, suggesting this. The purpose of this study was to analyze the prognostic value of preoperative NLR in an Argentine population of patients with nonmetastatic breast cancer, not exposed to neoadjuvant treatment.
Methods
UNASSIGNED
Retrospective multicenter cohort study that includes patients over 18 years of age from three centers in the city and province of Buenos Aires who have had surgery for early breast cancer between January 1, 1999, and December 31, 2014. Based on the previous literature, a cutoff value of 2.0 was defined.
Results
UNASSIGNED
A total of 791 patients were eligible for the analysis. Median age was 55 years (IQR 45-65). Median NLR was 1.92 (IQR 1.50-2.56). The distribution of groups according to the 8th edition of the AJCC was 54.1% for stage I, 35.6% stage II, and 10.4% stage III. Among the different tumor phenotypes, 79.0% were HR+/HER2-, 11.4% were HR+ or-/HER2+, and 9.2% were HR-/HER2-. With a median follow-up of 5.3 years, 112 patients (14.2%) had disease recurrence. Stage III patients had a higher NLR than stage I and stage II patients (
Conclusion
UNASSIGNED
We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias.
Identifiants
pubmed: 36590145
doi: 10.1159/000525287
pii: brc-0017-0546
pmc: PMC9801394
doi:
Types de publication
Journal Article
Langues
eng
Pagination
546-553Informations de copyright
Copyright © 2022 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Oncology. 2007;73(3-4):215-20
pubmed: 18424885
Front Immunol. 2020 Aug 07;11:1779
pubmed: 32849640
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
ESMO Open. 2016 Mar 7;1(2):e000038
pubmed: 27843594
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
J Clin Oncol. 2010 Apr 1;28(10):1684-91
pubmed: 20194857
J Clin Oncol. 2011 Oct 20;29(30):4014-21
pubmed: 21911717
Medicine (Baltimore). 2017 Nov;96(45):e8101
pubmed: 29137007
Nat Rev Cancer. 2013 Nov;13(11):759-71
pubmed: 24154716
Cancer Res Treat. 2019 Apr;51(2):649-663
pubmed: 30064200
Pancreas. 2006 Jan;32(1):22-8
pubmed: 16340740
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
PLoS One. 2015 Sep 03;10(9):e0136752
pubmed: 26336064
FEBS Open Bio. 2015 May 12;5:502-7
pubmed: 26137435
Breast Cancer Res Treat. 2021 Jan;185(2):261-279
pubmed: 33011829
Onco Targets Ther. 2018 May 17;11:2901-2910
pubmed: 29844687
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719